257 related articles for article (PubMed ID: 31992690)
1. Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter.
Tian YN; Chen HD; Tian CQ; Wang YQ; Miao ZH
Cell Death Dis; 2020 Jan; 11(1):71. PubMed ID: 31992690
[TBL] [Abstract][Full Text] [Related]
2. Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity.
Chen HD; Chen CH; Wang YT; Guo N; Tian YN; Huan XJ; Song SS; He JX; Miao ZH
Int J Cancer; 2019 Aug; 145(3):714-727. PubMed ID: 30675909
[TBL] [Abstract][Full Text] [Related]
3. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.
Shao Z; Lee BJ; Rouleau-Turcotte É; Langelier MF; Lin X; Estes VM; Pascal JM; Zha S
Nucleic Acids Res; 2020 Sep; 48(17):9694-9709. PubMed ID: 32890402
[TBL] [Abstract][Full Text] [Related]
4. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
5. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
6. Regulation of FOXO1-mediated transcription and cell proliferation by PARP-1.
Sakamaki J; Daitoku H; Yoshimochi K; Miwa M; Fukamizu A
Biochem Biophys Res Commun; 2009 May; 382(3):497-502. PubMed ID: 19281796
[TBL] [Abstract][Full Text] [Related]
7. Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.
Rank L; Veith S; Gwosch EC; Demgenski J; Ganz M; Jongmans MC; Vogel C; Fischbach A; Buerger S; Fischer JM; Zubel T; Stier A; Renner C; Schmalz M; Beneke S; Groettrup M; Kuiper RP; Bürkle A; Ferrando-May E; Mangerich A
Nucleic Acids Res; 2016 Dec; 44(21):10386-10405. PubMed ID: 27694308
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
9. PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Lai Y; Kong Z; Zeng T; Xu S; Duan X; Li S; Cai C; Zhao Z; Wu W
Oncol Rep; 2018 Apr; 39(4):1901-1909. PubMed ID: 29393407
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
11. Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Andronikou C; Rottenberg S
Trends Mol Med; 2021 Jul; 27(7):630-642. PubMed ID: 34030964
[TBL] [Abstract][Full Text] [Related]
12. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
[TBL] [Abstract][Full Text] [Related]
13. NF-κB and Poly (ADP-ribose) Polymerase 1 Form a Positive Feedback Loop that Regulates DNA Repair in Acute Myeloid Leukemia Cells.
Li D; Luo Y; Chen X; Zhang L; Wang T; Zhuang Y; Fan Y; Xu J; Chen Y; Wu L
Mol Cancer Res; 2019 Mar; 17(3):761-772. PubMed ID: 30559256
[TBL] [Abstract][Full Text] [Related]
14. PARP1 negatively regulates transcription of BLM through its interaction with HSP90AB1 in prostate cancer.
Huang M; Chen L; Guo Y; Ruan Y; Xu H
J Transl Med; 2023 Jul; 21(1):445. PubMed ID: 37415147
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis.
Kiss B; Szántó M; Hegedűs C; Antal D; Szödényi A; Márton J; Méhes G; Virág L; Szegedi A; Bai P
Exp Dermatol; 2020 Jan; 29(1):79-85. PubMed ID: 31755591
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells.
Wu W; Kong Z; Duan X; Zhu H; Li S; Zeng S; Liang Y; Iliakis G; Gui Z; Yang D
Biochem Biophys Res Commun; 2013 Dec; 442(1-2):127-32. PubMed ID: 24239883
[TBL] [Abstract][Full Text] [Related]
17. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.
Kim C; Wang XD; Yu Y
Elife; 2020 Aug; 9():. PubMed ID: 32844745
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase 1 expression.
Zhang Y; Huang J; Huang Y; Zhang S; Wu W; Long H; Duan X; Lai Y; Wu W
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179075
[TBL] [Abstract][Full Text] [Related]
19. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
[TBL] [Abstract][Full Text] [Related]
20. PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1.
Liu L; Kong M; Gassman NR; Freudenthal BD; Prasad R; Zhen S; Watkins SC; Wilson SH; Van Houten B
Nucleic Acids Res; 2017 Dec; 45(22):12834-12847. PubMed ID: 29121337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
